Gilead Sciences has beefed up its pipeline with an agreement to buy CymaBay Therapeutics and its seladelpar drug for rare liver disease primary biliary cholangitis (PBC), which has been filed for ...

CymaBay Therapeutics has scrapped two mid-stage trials of seladelpar in non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC), ending development of its lead drug.

As part of the FDA accelerated approval, Gilead has initiated a confirmatory long-term outcomes study, called AFFIRM ... pipeline in March 2024, when CymaBay Therapeutics Inc. was acquired ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...